Clinical Trials on Hodgkin's Disease

Total 379916 results

Centre Hospitalier Universitaire Dijon

Recruiting

Living Conditions After Non-Hodgkin's Lymphoma in France (LymphoVie 2)

Non-hodgkin's Lymphoma

France
Xynomic Pharmaceuticals, Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Active, not recruiting

A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients

Non Hodgkin Lymphoma

China
MorphoSys AG

Completed

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States, Belgium, Germany, Hungary, Italy, Poland, Spain
Gilead Sciences

Terminated

Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma

United States
Assiut University

Completed

Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma

Non Hodgkin Lymphoma

Egypt
Novartis Pharmaceuticals

Completed

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

Neoplasms | Non-Hodgkin Lymphoma

United States, Netherlands
Institut Paoli-Calmettes

Completed

Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma (R2)

Non-Hodgkin Lymphoma

France
University of Belgrade

Unknown

Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma (Lymphoseed)

Non-hodgkin Lymphoma

Serbia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First Affiliated Hospital of Zhengzhou University

Unknown

CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma

Non Hodgkin Lymphoma

China
Nordic Nanovector

Withdrawn

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

Non-Hodgkin Lymphoma

Germany
Samsung Medical Center
Millennium Pharmaceuticals, Inc.

Completed

Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas (BRAN)

Non-Hodgkin Lymphoma

Korea, Republic of
Beijing Immunochina Medical Science & Technology...
Peking University Cancer Hospital & Institute

Unknown

Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients

Non Hodgkin Lymphoma

China
Centre Leon Berard
Amgen

Terminated

Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation (PALM2)

Non Hodgkin Lymphoma

France
Radboud University Medical Center

Unknown

PEARL Study: Improvement of Non-Hodgkin's Lymphoma Care

Non-Hodgkin Lymphoma

Netherlands
Merck KGaA, Darmstadt, Germany

Completed

EMD 521873 in Advanced Solid Tumors, MTD Finding

Non-Hodgkin Lymphoma

Germany, Switzerland
Genzyme, a Sanofi Company

Completed

Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL

Non Hodgkin Lymphoma

Italy
Asociacion Espanola de Hematologia y Hemoterapia

Completed

Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma

Non Hodgkin Lymphoma

Spain
Instituto Nacional de Cancerologia de Mexico

Unknown

Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.

Non-Hodgkin Lymphoma

Mexico
Chiron Corporation

Terminated

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

China
Guangzhou Gloria Biosciences Co., Ltd.

Unknown

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Classical Hodgkin's Lymphoma

China
University of Birmingham
Millennium Pharmaceuticals, Inc.; Leukaemia Lymphoma Research

Completed

A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity (BREVITY)

Hodgkin Disease

United Kingdom
Institut Paoli-Calmettes

Completed

Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016 (HEMAJA)

Hodgkin Lymphoma | Acute Leukemia | Non-hodgkin Lymphoma | Malignant Haemopathies

France
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (Yosemite)

Indolent Non-Hodgkin's Lymphomas

United States, Korea, Republic of, Hungary, United Kingdom, Australia, Singapore, Japan, Taiwan, Israel, Italy, Spain, Czechia, Russian Federation, France, Poland, Romania, Germany, Portugal, Sweden
University of Cologne

Completed

HD18 for Advanced Stages in Hodgkins Lymphoma

Hodgkins Lymphoma

Germany
Shi, Patricia, M.D.
Genzyme, a Sanofi Company

Unknown

Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection

Multiple Myeloma | Non-Hodgkins Lymphoma

United States
Juventas Cell Therapy Ltd.

Not yet recruiting

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma
Sun Yat-sen University

Recruiting

The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Mature B Cell Non-Hodgkins Lymphoma (NHL).

Non-hodgkin Lymphoma

China
Swiss Group for Clinical Cancer Research

Terminated

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Non-Hodgkin Lymphoma

Switzerland
Gilead Sciences

Terminated

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States, France
Children's Hospital Los Angeles

Completed

Brown Fat Activity and White Fat Accumulation

Hodgkins Lymphoma | Non-hodgkins Lymphoma

United States
Sanofi

Completed

Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma

Lymphoma | Non-Hodgkin

United States
S*BIO

Completed

A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

Lymphoma, Malignant | Hodgkin's Lymphoma | B Cell Lymphoma

United States
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (Bridalveil)

Indolent Non-Hodgkin's Lymphomas

United States, Korea, Republic of, Canada, Spain, Taiwan, France, Australia, United Kingdom, Poland, Italy, Israel, Czechia, Germany, Russian Federation, Sweden
Pfizer

Terminated

Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)

Hodgkins Lymphoma

United Kingdom, United States, Italy
German High-Grade Non-Hodgkin's Lymphoma Study...
Deutsche Krebshilfe e.V., Bonn (Germany)

Completed

Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma (NHL)

Germany
Hoffmann-La Roche
AbbVie

Completed

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Follicular Lymphoma

United States, Italy, Canada, Australia, Belgium, United Kingdom, Germany, France
Ascenta Therapeutics

Completed

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

Follicular Lymphoma

United States
Innate Pharma

Recruiting

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States, Australia
Cho Pharma Inc.

Recruiting

A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Non-Hodgkin Lymphoma

Taiwan, United States
Abramson Cancer Center at Penn Medicine

Recruiting

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

Non Hodgkin Lymphoma

United States
Artiva Biotherapeutics, Inc.

Recruiting

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States
University of Texas Southwestern Medical Center

Recruiting

'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

Non-Hodgkin Lymphoma

United States
Ruijin Hospital

Recruiting

A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma

Non Hodgkin Lymphoma

China
Chinese PLA General Hospital

Recruiting

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Non Hodgkin Lymphoma

China
Zentera Therapeutics HK Limited

Terminated

A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

China
Hoffmann-La Roche

Completed

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Non-Hodgkin Lymphoma

Algeria, Morocco, Tunisia
Rhizen Pharmaceuticals SA

Completed

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Non Hodgkin Lymphoma

United States, Australia
Abramson Cancer Center of the University of Pennsylvania

Terminated

Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

Non-Hodgkin Lymphoma

United States
Soonchunhyang University Hospital

Completed

BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma (CISL)

Non-hodgkin Lymphoma

Korea, Republic of

3

Subscribe